/Analysis

Lost and found: Booking.com in India

Moulishree Srivastava

A wildcard entry into the IPL rights scramble

Venkat Ananth

The Last Line Uber India Crosses?

Venkat Ananth

Bigbasket’s fight with Grofers could end soon but there’s another one brewing

Patanjali Pahwa

How I was wrong about OYO’s Ponzi scheme

Sumanth Raghavendra

• Free Reads

From macro to micro: The fine line India’s IT industry is treading

Moulishree Srivastava

Unpacking Flipkart’s latest funding round

Sumanth Raghavendra

Check-in, check-out: India’s fast-moving health bureaucracy

Seema Singh, Ruhi Kandhari

• Free Reads

Flipkart: Dance of the dragons

Rohin Dharmakumar

The gap you can’t ignore

Nikita Takkar, Arundhati Ramanathan, Ruhi Kandhari

• Free Reads

Reliance Jio versus conventional wisdom

Patanjali Pahwa

M.A.D. (Mutually Assured Destruction)

Rohin Dharmakumar

Today’s PSLV launch could create history. And a new market for Isro

Gopal Raj

• Free Reads

E-commerce unicorns and payments ponycorns

Rohin Dharmakumar

How charity is fuelling a superbug in India

Ruhi Kandhari

• Free Reads

Humanising Algorithms

Seema Singh

• Free Reads

Arranged Marriage

Rohin Dharmakumar

Google India’s 2017 Focus

Venkat Ananth

• Free Reads

The evolution of E-commerce transactions

Rohin Dharmakumar

Winter Has Come to Media

Rohin Dharmakumar

You can win. On social media

Patanjali Pahwa

India’s misinformation crisis: Fake or real?

Venkat Ananth

• Free Reads

YepMe Wants To Fly

Moulishree Srivastava

So how many people watch Arnab Goswami every night?

Ashish K. Mishra

The Interconnect Wars

Rohin Dharmakumar

Inside the public policy battle between Ola and Uber

Venkat Ananth

Sequoia: The art of the sell

Ashish K. Mishra, Rohin Dharmakumar, Sumanth Raghavendra

• Long Reads

A sweet spot called BlaBlaCar

Patanjali Pahwa

The Goa hypothesis

Sumanth Raghavendra

Gatekept

Rohin Dharmakumar

• Free Reads

The Great Pharma U-Turn

Seema Singh

Big Billion Days and the Flipkart Spit N’ Polish Machine

Team Ken

A dubious diabetes drug, regulatory confusion, and a potential PIL

Seema Singh

Three things Indian medtech must get right, and one that is still open ended

Seema Singh

• Free Reads

Endgame Ola

Rohin Dharmakumar

• Free Reads

Jabong – the un-making of a unicorn

Team Ken